Arora, Prerna

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 897

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Hoffmann, M., Hofmann-Winkler, H., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Arora, P., Sidarovich, A., Moldenhauer, A.-S., Winkler, M. S., et al. (2021) · Cell Reports

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 258

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation

Hoffmann, M., Behrens, G. M. N., Arora, P., Kempf, A., Nehlmeier, I., Cossmann, A., Manthey, L., Dopfer-Jablonka, A., & Pöhlmann, S. (2023) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 66